Articles by Hans-Jürgen Stellbrink

Antiviral Activity, Pharmacokinetics, and Safety of the HIV-1 Protease Inhibitor TMC310911, Coadministered With Ritonavir, in Treatment-Naive HIV-1–Infected Patients

Stellbrink, Hans-Jürgen; Arastéh, Keikawus; Schürmann, Dirk; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 65(3):283-289, March 1, 2014.

Increased Interferon Alpha Expression in Circulating Plasmacytoid Dendritic Cells of HIV-1-Infected Patients

Lehmann, Clara; Harper, Jill M; Taubert, Dirk; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 48(5):522-530, August 15, 2008.

Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

Nelson, Mark; Arastéh, Keikawus; Clotet, Bonaventura; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 40(4):404-412, December 1, 2005.

Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks

Trottier, Benoit; Walmsley, Sharon; Reynes, Jacques; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 40(4):413-421, December 1, 2005.